Fisetin for Cognitive Function

Verdict: No human evidence; preclinical only

There is currently no human trial evidence that fisetin improves cognitive function or prevents dementia; all supporting data come from mouse studies, and major regulators and clinics do not endorse this use.

U ⚫ U Unverified Taiwan Regulatory Restriction

🔬Why this grade7-layer evidence engine

This claim is graded Unverified because every cited study is preclinical, with zero published human randomized trials measuring cognitive outcomes. Four mouse experiments report benefit: nano-fisetin eased memory deficits and lowered TNF-alpha/IL-6 in amyloid-beta mice over three weeks (PMID 39552578); fisetin reduced cognitive decline in rapidly aging SAMP8 mice over 28 weeks (PMID 28575152); and it preserved learning and memory in transgenic Alzheimer's mice over 36 weeks (PMID 24341874). A related review covers the fisetin derivative CMS121 but reports no human cognition data (PMID 39422940).

Animal results do not transfer reliably to people, and a practical gap compounds the uncertainty: the preclinical doses (roughly 5-25 mg/kg) far exceed typical human supplement doses, and fisetin is poorly absorbed orally. Ongoing early-phase human trials have not yet reported cognitive results.

Authorities reinforce the cautious grade. The FDA issued a warning letter over illegal disease claims for a fisetin product, and Health Canada permits only a basic antioxidant claim at 100 mg/day, not any anti-aging or cognitive use. Mayo Clinic explicitly argues against using commercial fisetin, and the Alzheimer's Association states no supplement has been proven to benefit cognitive function or brain health.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.41
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
U · Taiwan Regulatory Restriction
Confidence
74%
Broadly consistent
Evidence level
E10
Mechanism / case reports / no human evidence

How strongly each layer supports this effect

lower = less supportive
L11 AI re-checkIndependent read
0.20
L2 PubMedPrimary literature
0.40
L5 Clinical bodiesAuthoritative stance
0.40
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.50
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.415
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 僅有 E10 級證據 (cohort/animal/mechanism),不足以下結論
  4. tier_strict_requirement_check — C 級條件未達 (需 E1-E8;實際 E10 僅機轉)
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (4)L2 · primary research & systematic reviews

Nanoformulated fisetin ameliorates Alzheimer's disease via reducing proinflammatory cytokines and activating NRF2/HO-1
PMID: 39552578 2024 Animal Study
Finding: Nano-fisetin significantly improved memory and motor deficits, reduced TNF-α/IL-6 and oxidative stress, activated NRF2/HO-1 (p-values not extracted).
🟠 Limited quality
View on PubMed
CMS121, a Novel Drug Candidate for the Treatment of Alzheimer's Disease and Age-Related Dementia
PMID: 39422940 2024 Animal Study
Finding: CMS121 maintains cognitive function in preclinical AD models; IND-enabling toxicology completed; no human cognition data yet.
🟠 Limited quality Academic
View on PubMed
Fisetin Reduces the Impact of Aging on Behavior and Physiology in the Rapidly Aging SAMP8 Mouse
PMID: 28575152 2017 Animal Study
Finding: Fisetin reduced cognitive deficits in old SAMP8 mice and restored synaptic/inflammation markers vs untreated controls.
🟠 Limited quality Government
View on PubMed
Modulation of p25 and inflammatory pathways by fisetin maintains cognitive function in Alzheimer's disease transgenic mice
PMID: 24341874 2014 Animal Study
Finding: Fisetin prevented learning/memory deficits in AD-Tg mice; treated mice spent significantly more time in target quadrant vs untreated AD mice.
🟠 Limited quality Government
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
Fisetin is a potent anti-inflammatory agent and directly inhibits the activity pro-inflammatory cytokines such as TNFα, NF-κB, and IL6. source↗
L4b EU EFSA
Cautious
L4e WHO
Supportive
Medicinal Ingredient: 3,3',4',7-Tetrahydroxyflavone 100.0 mg. Recommended Use or Purpose: Provides Antioxidant. Provides antioxidants that help protect against the oxidative damage caused by free radicals. Recommended Dose: Adults (19 years and older): 1 capsule daily. Cautions and Warnings: Consult a healthcare practitioner prior to use if you are taking opioids, anti-inflammatory medications,… source↗
L5a NIH Office of Dietary Supplements
Cautious
L5b Mayo Clinic
Cautious
Our findings argue against what many people are already doing — using commercial products like quercetin or related compounds like fisetin that may show some senolytic properties. source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬4 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-cognitive-function-INT-fisetin-001 繁體中文版 →